Sign In
Buy AVIR
$4.70
-0.0400 (-0.84%)
At Close: Jul 31, 2026
First Clinical Data for Coadministration of Bemnifosbuvir and Ruzasvir Show Combination Was Well Tolerated in a Phase 1 Study
Atea Pharmaceuticals, Inc. (AVIR) Q3 2023 Earnings Call Transcript
06:51pm, Wednesday, 08'th Nov 2023
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Jonae Barnes - SVP, IR & Corporate Communications Jean-Pierre Sommadossi - F
Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
04:05pm, Wednesday, 08'th Nov 2023
P atient enrollment continues in global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for COVID-19; first interim analysis expected 1Q24
Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences
07:00am, Wednesday, 08'th Nov 2023
BOSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral
Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023
07:00am, Wednesday, 01'st Nov 2023
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral
Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
07:00am, Wednesday, 06'th Sep 2023
BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral
Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
04:05pm, Tuesday, 08'th Aug 2023
BOSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral
Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023
07:00am, Tuesday, 01'st Aug 2023
BOSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
04:20pm, Monday, 05'th Jun 2023
BOSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral
